EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Top advances of the year: Precision oncology

Aakash Desai, Neha K Reddy iD, Vivek Subbiah iD

Cancer · 2023

DOI: 10.1002/cncr.34743 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2023. Verfasst von Aakash Desai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, MayoClinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Precision Medicine, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advent of precision medicine has changed the landscape of oncologic biomarkers, drug discovery, drug development, and, more importantly, outcomes for patients with cancer. Precision oncology entails the genomic profiling of tumors to detect actionable aberrations. The advances in clinical next‐generation sequencing from both tumor tissue and liquid biopsy and availability of targeted therapies has rapidly entered mainstream clinical practice. In this review, recent major developments in precision oncology that have affected outcomes for patients with cancer are discussed. Rapid clinical development was seen of targeted agents across various mutational profiles such as KRASG12C (which was considered “undruggable” for almost 4 decades), Exon 20 insertions, and RET mutations. Approaches to precision chemotherapy delivery by the introduction of antibody drug conjugates in the armamentarium against lung cancer has been appreciated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineLung NeoplasmsHumansMolecular Targeted TherapyBiomarkers, TumorMedical OncologyHigh-Throughput Nucleotide SequencingMutation

Stichwörter der Autor:innen

antibody drug conjugatescanceroncogenic driverprecision oncologytargeted therapy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Division of Medical Oncology, MayoClinic, Rochester, Minnesota, USA.
  • Department of Internal Medicine, The University of Texas at Austin Dell Medical School, Austin, Texas, USA.
  • Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Neha K Reddy, Vivek Subbiah

Zitieren

APA

Desai, A., Reddy, N. K., & Subbiah, V. (2023). Top advances of the year: Precision oncology. Cancer. https://doi.org/10.1002/cncr.34743

Vancouver

Desai A, Reddy NK, Subbiah V. Top advances of the year: Precision oncology. Cancer. 2023. doi:10.1002/cncr.34743

BibTeX
@article{Desai2023,
  author = {Desai, Aakash and Reddy, Neha K and Subbiah, Vivek},
  title = {Top advances of the year: Precision oncology},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34743}
}
Kostenlos starten →